Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club
- 201 Downloads
Paget’s disease of bone (PDB) is a potentially crippling condition. Pain, fracture, spinal stenosis, nerve entrapment, vascular steal syndrome, secondary osteoarthritis, bone deformity, dental problems, deafness, excessive bleeding during orthopaedic surgery, rare sarcomatous degeneration, and hypercalcaemia constitute complications that may impair the quality of life. The therapeutic approach varies from symptomatic (analgesics, anti-inflammatory drugs) to more specific drugs such as increasingly potent bisphosphonates. Studies such as the PRISM study should in the future help to determine the superiority or not of aggressive treatment over symptomatic treatment in the prevention of complications. Various oral and/or intravenous (I.V.) bisphosphonates have been tested and are currently on the market. The most recently available nitrogen-containing bisphosphonate, I.V. zoledronic acid, is the most potent therapy available for the treatment of PDB. Its therapeutic efficacy, its long-term effect on biologic activity and its good tolerance currently supports its use as a first-line therapeutic option in patients suffering from PDB.
KeywordsBisphosphonates Calcitonin Paget’s disease of bone Therapy
We thank Marie-Christine Hallot for expert technical assistance.
Conflicts of interest
J.P. Devogelaer participated in industry-supported trials on salcatonin (Sandoz, Novartis), etidronate (Procter & Gamble), tiludronate (Sanofi), risedronate (Procter & Gamble) and zoledronic acid (Novartis). Lecture fees or paid advisory board: Lilly, MSD, Novartis, Roche, Servier.
J.M. Kaufman and S. Goemaere declare themselves to have participated in company-sponsored clinical trials involving alendronate (Merck & Co), risedronate (Procter & Gamble), tiludronate (Sanofi-Synthelabo), ibandronic acid (Roche) and zoledronic acid (Novartis), and to have received speaker’s fees and research grants from Procter & Gamble, Sanofi-Aventis, Merck & Co, Roche and GlaxoSmithKline.
Jean-Yves Reginster on behalf of the Department of Public Health Epidemiology and Health Economics of the University of Liège, Liège, Belgium. Date: March 12, 2008. Consulting fees or paid advisory boards: Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB. Lecture fees when speaking at the invitation of a commercial sponsor: Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk. Grant Support from Industry: Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier.
P. Bergmann, J.J. Body, Y. Boutsen and S. Rozenberg declare that they have no conflict of interest in the field.
S. Boonen is Senior Clinical Investigator of the Fund for Scientific Research—Flanders, Belgium (F.W.O.—Vlaanderen) and holder of the Leuven University Chair in Metabolic Bone Diseases, supported by Roche & GSK. Dr. Boonen reports having received consulting fees, lecture fees and research support from Novartis, Sanofi-Aventis and Procter & Gamble Pharmaceuticals.
- 1.Paget J (1877) On a form of chronic inflammation of bones (Osteitis Deformans). Med Chir Trans Lond 60:37–63Google Scholar
- 2.Hosking D, Meunier PJ, Ringe HD, Reginster J-Y, Gennari C (1996) Fortnightly review: Paget’s disease of bone: diagnosis and management. Br Med J 312:491–494Google Scholar
- 9.US Department of Health and Human Services. Agency for Health care policy and research (1993) Acute pain management: operative or medical procedures and trauma. Clinical Practice Guidelines n°1. AHCPR Publication # 92–0023, p 107Google Scholar
- 10.Devogelaer JP, Nagant de Deuxchaisnes C (2003) Paget’s disease of bone. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology, vol 2, 3rd edn. Mosby, London, pp 2139–2147Google Scholar
- 15.Rapado A, Jimenez J, Morales A, Carbonell J, Del Pino J (1999) Patterns of diagnosis of Paget’s disease in Spain. J Bone Miner Res 14 [Suppl 2]:S96–S98Google Scholar
- 18.Detheridge FM, Guyer PB, Barker DJP (1982) European distribution of Paget’s disease of bone. Br Med J 285:1005–1008Google Scholar
- 22.Fernandez S, Tiessen L, Powell-Tuck J, Beck S, Johansen A (2007) Pagetic hip fracture. How big is the problem? Osteoporos Int 18 [Suppl 3]:S292Google Scholar
- 27.Nagant de Deuxchaisnes C, Devogelaer JP (1989) Surveillance et suivi à long terme de la maladie osseuse de Paget. In: Simon L, Sébert JL, Hérisson C (eds) La maladie osseuse de Paget: actualités. Masson, ParisGoogle Scholar
- 28.Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. Dunitz, LondonGoogle Scholar
- 31.Ralston SH, Langston AL, Campbell MK, MacLennan G, Selby PL, Fraser WD (2006) Initial results from the PRISM study: a large randomised comparative trial of intensive versus symptomatic treatment for Paget’s disease. J Bone Miner Res 21 [Suppl 1]:LB1Google Scholar
- 34.Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41:354–360PubMedCrossRefGoogle Scholar
- 45.Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423PubMedCrossRefGoogle Scholar
- 59.Peris P, Alvarez L, Vidal S, Martinez MA, Monegal A, Guañabens N (2007) Treatment with tiludronate has a similar effect to risedronate on Paget’s disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheum 25:206–210Google Scholar
- 60.Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget’s risedronate/etidronate study group (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 106:513–520Google Scholar
- 67.Lecompte P, Devogelaer JP, Kaufman JM, Goemaere S, Geusens P, Engbersen A (2005) Cost-effectiveness analysis of Aclasta in Paget’s disease of bone in Belgium. Value Health 8:A73Google Scholar
- 68.Kurth AA, Kotowa W, Goel D, Maiwenn JA (2006) Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget’s disease of the bone in Germany. Value Health 9(6):A220Google Scholar